Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma

Oligonucleotides

Volumn 20, Issue 4, 2010, Pages 183-190

  Şalva, Emine ^a   Kabasakal, Levent ^a   Eren, Fatih ^a   Çakalaǧaoǧlu, Fulya ^b   Özkan, Naziye ^a   Akbuǧa, Jülide ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Izmir Ataturk Education and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MESSENGER RNA; SHORT HAIRPIN RNA VASCULAR ENDOTHELIAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CHITOSAN; DRUG DELIVERY SYSTEMS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 77955689271     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2010.0241     Document Type: Article

References (36)

1. ALAM, S.A.K.M., FLOREY, O., WEBER, M., PILLAI, R.G., CHAN, C., TAN, P.H., LECHLER, R.I., MCCLURE, M.O., HASKARD, D.O., and GEORGE, A.J.T. (2006). Knockdown of mouse VCAM-1 by vector-based siRNA. Transpl. Immunol. 16, 185-193.
2. BEHLKE, M.A. (2006). Progress towards in vivo use of siRNAs. Mol. Ther. 13, 645-670.
3. BOLAT, F., KAYASELÇ UK, F., NURSAL, T.Z., ÇAKALA-GAOGLU, F., et al. (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J. Exp. Clin. Cancer Res. 25, 365-372.
4. BORCHARD, G. (2001). Chitosans for gene delivery. Adv. Drug Deliv. Rev. 52, 145-150.
5. CHEN, Z., VARNEY, M.L., BACKORA, M.W., COWAN, K., SOLHEIM, J.C., TALMAGE, J.E., and SINGH, R.K. (2005). Downregulation of VEGF-C expression using siRNA vectors in Mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65, 9004-9011.
6. CHIEN, P.Y., WANG, J., CARBONORA, D., LEI, S., MILLER, B., SHEIKH, S., ALI, S.M., AHMAD, M.U., and AHMAD, I. (2005). Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12, 321-328.
7. DASS, C.R., and CHOONG, P.F.M. (2008). The use of chitosan formulations in cancer therapy. J. Microencapsul. 25, 275-279.
8. FILLEUR, S., COURTIN, A., ALI, S., GUGLIELMI, J., MERLE, C., BELLAN, A., CLEZARDIN, P., and CABON, F. (2003). siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 63, 3919-3922.
9. GUMINSKA, M., IGNACAK, J., and WOJCK, E. (1996). In vitro inhibitory effect of chitosan and its degradation products on energy metabolism in Ehrlich ascites tumor cells. Pol. J. Pharmacol. 48, 495-501.
10. HOGREFE, R.I., LEBEDEV, A.V., ZON, G., PIROLLO, K.F., RAIT, A., ZHOU, Q., YU, W., and CHANG, E.H. (2006). Chemically modified short interfering hybrids (siHYBRIDS): nanoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25, 889-907.
11. HOWARD, K.A., RAHBEK, U.L., LIU, X., DAMGAARD, C.K., GLUD, S.Z., ANDERSEN, M.Ø., HOVGAARD, M.B., SCHMITZ, A., NYENGAARD, J.R., BESENBACHER, F., and KJEMS, J. (2006). RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484.
12. JERE, D., XU, C.X., AROTE, R., YUN, C.H., CHO, M.H., and CHO, C.S. (2008). Poly(b-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. Biomaterials 29, 2535-2547.
13. JIANG, H.L., XU, C.X., KIM, Y.K., AROTE, R., JERE, D., LIM, H.T., CHO, M.H., and CHO, C.S. (2009). The suppression of lung tumoriogenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 30, 5844-5852.
14. KIM, S.H., JEONG, J.H., LEE, S.H., KIM, S.W., and PARK, T.G. (2008). Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129, 107-116.
15. KIM, W.J., CHANG, C.W., LEE, M., and KIM, S.W. (2007). Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J. Control. Release 118, 357-363.
16. KLEINMAN, M.E., YAMADA, K., TAKEDA, A., CHANDRA-SEKARAN, V., NOZAKI, M., BAFFI, J.Z., ALBUQUERAUE, R.J., YAMASAKI, S., HAYA, M., PAN, Y., APPUKUTTAN, B. GIBBS, D., YANG, Z., KARIKO, K., AMABATI, B.K., WILGUS, T.A., DIPIETRO, L.A., SAKURAI, E., ZHANG, K., SMITH, J.R., TAYLOR, E.W., and AMBATI, J. (2008). Sequence and target independent angiogenesis suppression by siRNA via TLR 3. Nature 452, 591-597.
17. LEE, S.L., KIM, D.H., ALLUIN, J., ROBBINS, M., GU, S., LI, H., KIM, J., SALVATERRA, P.M., and ROSSI, J.J. (2008). Functional and intracellular localization properties of U6 promoter-expressed siRNAs, shRNAs and chimeric VA1 shRNAs in mammalian cells. RNA 14, 1823-1833.
18. LIU, X., HOWARD, K.A., DONG, M., ANDERSEN, M.Ø., RAHBEK, U.L., JOHNSEN, M.G., HANSEN, O.C., BESEN-BECHER, F., and KJEMS, J. (2007). The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28, 1280-1288.
19. MA, Z., LI, J., HE, F., WILSON, A., PITT, B., and LI, S. (2005). Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755-759.
20. MATSUMOTO, G., KUSHIBIKI, T., KINOSHITA, Y., LEE, U., OMI, Y., KUBOTA, E., and TABATA, Y. (2006). Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci. 97, 313-321.
21. MOBIUS, C., DEMUTH, C., AIGNER, T., WIEDMANN, M., WITTEKIND, C., MOSSNER, J., HAUSS, J., and WITZIGMANN, H. (2007). Evaluation of VEGF A expression and microvas-cular density as prognostic factors in extrahepatic cholangio-carcinoma. J. Cancer Surg. 33, 1025-1029.
22. NIOLA, F., EVANGELISTI, C., CAMPAGNALO, L., MASSA-LINI, S., BUE, M.C., MANGIOLA, A., MASOTTI, A., MAIRA, G., FARACE, M.G., and CIAFRE, S.A. (2006). A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 5, 174-179.
23. OH, Y.-K., and PARK, T.G. (2009). siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61, 850-862.
24. RAO, D.D., VORHIES, J.S., SENZER, N., and NEMUNAITIS, J. (2009). siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 61, 746-759.
25. RASKOPF, E., VOGT, A., SAUERBRUCH, T., and SCHMITZ, V. (2008). siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J. Hepatol. 49, 977-984.
26. RIBATTI, D. (2008). Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis 11, 3-10.
27. ROBBINS, M., JUDGE, A., and MACLACHLAN, I. (2009). siRNA and innate immunity. Oligonucleotides 19, 89-101.
28. SALVA, E., and AKBUGA, J. (2009). Comparison of silencing effect of chitosan/psiRNA complexes in different cell lines. Adv. Chitin Sci. XI, 203-208.
29. SCHIFFELERS, R.M., MIXSON, A.J., ANSARI, A.M., MARCEL, F., TANG, Q., ZHOUC, Q., XU, J., MOLEMAD, G., LU, P.Y., SCARIA, P.V., STORM, G., and WOODLE, M.C. (2005). Transporting silence: design of carriers for siRNA to angio-genic endothelium. J. Control. Release 109, 5-14.
30. SU, J., CHEN, T., and KANEKURA, A. (2009). A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett. 273, 140-147.
31. THOMPSON, H.J., and ADLAKHA, H. (1991). Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 51, 3411-3415.
32. TURHAL, N.S., DANE, F., DEDE, F., et al. (2004). 99m-Tc-MDP- Scintimammography in the evaluation of breast masses or tumor angiogenesis. Anticancer Res. 24, 1999-2006.
33. WANG, S.L., YAO, H.H., GUO, L.L., DONG, L., LI, S.G., GU, Y.P., and QIN, Z.H. (2009). Selection of optimal sites for TGFB1 gene silencing by chitosan-TPP nanoparticle-mediated delivery of shRNA. Cancer Genet. Cytogenet. 190, 8-14.
34. WANNENES, F., CIAFRE, S.A., NIOLA, F., FRAJESE, G., and FARACE, M.G. (2005). Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vas-cularization and growth of prostate cancer in vivo. Cancer Gene Ther. 12, 926-934.
35. ZHANG, S., ZHAO, B., JIANG, H., WANG, B., and MA, B. (2007). Cationic lipid and polymers mediated vectors for delivery of siRNA. J. Control. Release 123, 1-10.
36. ZHANG, Z., SUN, P., LIU, J., YAN, J., LIU, Y., YU, L., WANG, X., and YAN, Q. (2008). Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 1783, 287-296.